medicare

Mark Cuban pharmacy could save billions on prostate cancer, bladder drugs

Vanderbilt research found that a new drug company founded by entrepreneur Mark Cuban could save patients $1.29 billion a year based on 2020 Medicare Part D expenditures on just the nine most popular urological drugs.

Stacie Dusetzina, PhD, right, on the South Lawn of the White House with colleagues Rachel Sachs, JD, MPH, of Washington University St. Louis, left, and Michell Mello, PhD, of Stanford.

Researcher’s decade of analyzing the price of drugs leads to big reforms

Vanderbilt’s Stacie Dusetzina, PhD, and several colleagues were able to reflect recently on the South Lawn of the White House about how their contributions through research and data informed the provisions in the Inflation Reduction Act that will save older Americans on Medicare tens of thousands of dollars in out-of-pocket costs each year.

New study illustrates how much it would cost for cancer drugs covered under Medicare Part D

A new study by Vanderbilt researchers highlights how some older Americans diagnosed with cancer can face unlimited out-of-pocket spending for prescription drugs under the current structure of the Medicare Part D benefit.

Medicare beneficiaries without low-income subsidies were less likely to fill important prescriptions, new study finds

Vanderbilt research shows that Medicare Part D beneficiaries who did not receive federal subsidies to lower their out-of-pocket costs were nearly twice as likely as others to not fill prescriptions for serious health conditions like cancer or hepatitis C treatment.

Study examines long-term benefit of Two-Midnight Rule

Vanderbilt research is raising new questions about the long-term benefit and value of the so-called Medicare “Two-Midnight Rule” implemented in 2013 to reduce costly and potentially unnecessary inpatient hospital admissions

Dusetzina appointed to federal Medicare Payment Advisory Commission

Stacie Dusetzina, PhD, associate professor of Health Policy and Ingram Associate Professor of Cancer Research at Vanderbilt University School of Medicine, has been appointed to a three-year term on the Medicare Payment Advisory Commission (MedPAC).

1 2